The Glycome of Normal and Malignant Plasma Cells
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
The glycome, i.e. the cellular repertoire of glycan structures, contributes to important functions such as adhesion and intercellular communication. Enzymes regulating cellular glycosylation processes are related to the pathogenesis of cancer including multiple myeloma. Here we analyze the transcriptional differences in the glycome of normal (n = 10) and two cohorts of 332 and 345 malignant plasma-cell samples, association with known multiple myeloma subentities as defined by presence of chromosomal aberrations, potential therapeutic targets, and its prognostic impact. We found i) malignant vs. normal plasma cells to show a characteristic glycome-signature. They can ii) be delineated by a lasso-based predictor from normal plasma cells based on this signature. iii) Cytogenetic aberrations lead to distinct glycan-gene expression patterns for t(11;14), t(4;14), hyperdiploidy, 1q21-gain and deletion of 13q14. iv) A 38-gene glycome-signature significantly delineates patients with adverse survival in two independent cohorts of 545 patients treated with high-dose melphalan and autologous stem cell transplantation. v) As single gene, expression of the phosphatidyl-inositol-glycan protein M as part of the targetable glycosyl-phosphatidyl-inositol-anchor-biosynthesis pathway is associated with adverse survival. The prognostically relevant glycome deviation in malignant cells invites novel strategies of therapy for multiple myeloma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among 243 glycogenes, 60 showed a significantly higher expression in MM than normal plasma cell samples, while 20 showed a lower one [141].”
From GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review (2022) · cites this paper as [141]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
A Model-Based Background Adjustment for Oligonucleotide Expression Arrays
Wu, Z., Irizarry, R. A., Gentleman, R., Martinez-Murillo, F., & Spencer, F. (2004) · Journal of the American Statistical Association · doi:10.1198/016214504000000683 · Cited by 1,716 · cited 1×
“Statistical analysis Expression data were gcrma-preprocessed [43] and log2 transformed.”
MethodBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Kyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,296
A global test for groups of genes: testing association with a clinical outcome
Goeman, J. J., van de Geer, S. A., de Kort, F., & van Houwelingen, H. C. (2004) · Bioinformatics · doi:10.1093/bioinformatics/btg382 · Cited by 1,069 · cited 1×
“So both approaches have slightly different objectives [47].”
BackgroundShaughnessy, J. D., Zhan, F., Burington, B. E., Huang, Y., Colla, S., Hanamura, I., Stewart, J. P., Kordsmeier, B., Randolph, C., Williams, D. R., et al. (2007) · Blood · doi:10.1182/blood-2006-07-038430 · Cited by 914
Avet-Loiseau, H., Attal, M., Moreau, P., Charbonnel, C., Garban, F., Hulin, C., Leyvraz, S., Michallet, M., Yakoub-Agha, I., Garderet, L., et al. (2007) · Blood · doi:10.1182/blood-2006-08-040410 · Cited by 911
MAQC Consortium (2010) · Nature Biotechnology · doi:10.1038/nbt.1665 · Cited by 889
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053583 · Cited by 739 · cited 1×
“Survival data were validated by an independent cohort of 345 patients treated within the total therapy 2 (TT2) protocol [30].”
MethodGenetics and Cytogenetics of Multiple Myeloma
Fonseca, R., Barlogie, B., Bataille, R., Bastard, C., Bergsagel, P. L., Chesi, M., Davies, F. E., Drach, J., Greipp, P. R., Kirsch, I. R., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2876 · Cited by 687 · cited 1×
“Myeloma cells harbor a high median number of chromosomal aberrations [2,3] and multiple changes in gene expression compared to normal bone marrow plasma cells.”
BackgroundThe Glycosylphosphatidylinositol Anchor: A Complex Membrane-Anchoring Structure for Proteins
Paulick, M. G., & Bertozzi, C. R. (2008) · Biochemistry · doi:10.1021/bi8006324 · Cited by 600 · cited 1×
“associated with myeloma pathogenesis require GPI anchors [50].”
BackgroundCarbohydrate‐mediated cell adhesion in cancer metastasis and angiogenesis
Kannagi, R., Izawa, M., Koike, T., Miyazaki, K., & Kimura, N. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03219.x · Cited by 572
Filmus, J., Capurro, M., & Rast, J. (2008) · Genome Biology · doi:10.1186/gb-2008-9-5-224 · Cited by 556
Neben, K., Lokhorst, H. M., Jauch, A., Bertsch, U., Hielscher, T., van der Holt, B., Salwender, H., Blau, I. W., Weisel, K., Pfreundschuh, M., et al. (2012) · Blood · doi:10.1182/blood-2011-09-379164 · Cited by 356
Self-citationDerksen, P. W. B., Keehnen, R. M. J., Evers, L. M., van Oers, M. H. J., Spaargaren, M., & Pals, S. T. (2002) · Blood · doi:10.1182/blood.v99.4.1405 · Cited by 274
Heparanase Enhances Syndecan-1 Shedding
Yang, Y., MacLeod, V., Miao, H.-Q., Theus, A., Zhan, F., Shaughnessy, J. D., Sawyer, J., Li, J.-P., Zcharia, E., Vlodavsky, I., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611259200 · Cited by 264 · cited 1×
“by heparanase produced by myeloma cells or the bone marrow environment [21,22], can liberate these growth factors and promotes angiogenesis.”
BackgroundGlycan-dependent leukocyte adhesion and recruitment in inflammation
Lowe, J. B. (2003) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2003.08.002 · Cited by 249
Nair, B., van Rhee, F., Shaughnessy, J. D., Anaissie, E., Szymonifka, J., Hoering, A., Alsayed, Y., Waheed, S., Crowley, J., & Barlogie, B. (2010) · Blood · doi:10.1182/blood-2009-11-255620 · Cited by 201
Complement resistance of tumor cells: basal and induced mechanisms
Jurianz, K., Ziegler, S., Garcia-Schüler, H., Kraus, S., Bohana-Kashtan, O., Fishelson, Z., & Kirschfink, M. (1999) · Molecular Immunology · doi:10.1016/s0161-5890(99)00115-7 · Cited by 199 · cited 5×
“In order to remove the GPIanchored CD55 and CD59 proteins from the cell surface KMS12-BM and OPM-2 cells (16106 cells suspended in 400 ml PBS) were incubated with 40 mL phospholipase C (100 enzymatic units/ mL; Life Technologies, Darmstadt, Germany) for 1 h at 37uC prior to antibody staining.”
BackgroundInfluentialHose, D., Reme, T., Hielscher, T., Moreaux, J., Messner, T., Seckinger, A., Benner, A., Shaughnessy, J. D., Barlogie, B., Zhou, Y., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.030296 · Cited by 199 · cited 2×
“Quality controls were performed as previously published [26].”
MethodSelf-citationDeciphering the glycocode: the complexity and analytical challenge of glycomics
Pilobello, K. T., & Mahal, L. K. (2007) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.05.002 · Cited by 188
Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma
Harousseau, J.-L., & Moreau, P. (2009) · New England Journal of Medicine · doi:10.1056/nejmct0805626 · Cited by 186
Sprynski, A. C., Hose, D., Caillot, L., Réme, T., Shaughnessy, J. D., Barlogie, B., Seckinger, A., Moreaux, J., Hundemer, M., Jourdan, M., et al. (2009) · Blood · doi:10.1182/blood-2008-07-170464 · Cited by 173
Self-citationLong‐term outcome results of the first tandem autotransplant trial for multiple myeloma
Barlogie, B., Tricot, G. J., Van Rhee, F., Angtuaco, E., Walker, R., Epstein, J., Shaughnessy, J. D., Jagannath, S., Bolejack, V., Gurley, J., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06271.x · Cited by 163 · cited 1×
“This molecular heterogeneity is thought to transmit into very different survival times ranging from a few month to 15 or more years [4], with a median survival after conventional treatments of 3–4 years and 5–9 years after high-dose treatment followed by autologous stem-cell transplantation [5–7].”
BackgroundInduction of angiogenesis by normal and malignant plasma cells
Hose, D., Moreaux, J., Meißner, T., Seckinger, A., Goldschmidt, H., Benner, A., Mahtouk, K., Hillengaß, J., Reme, T. X., Vos, J. D., et al. (2009) · Blood · doi:10.1182/blood-2008-10-184226 · Cited by 153 · cited 2×
“vascular endothelial growth factor-A (VEGF-A), both produced by normal and malignant plasma cells [8,9].”
BackgroundMethodSelf-citationMahtouk, K., Hose, D., Raynaud, P., Hundemer, M., Jourdan, M., Jourdan, É., Pantesco, V., Baudard, M., Vos, J. D., Larroque, M., et al. (2007) · Blood · doi:10.1182/blood-2006-08-043232 · Cited by 137 · cited 2×
“by heparanase produced by myeloma cells or the bone marrow environment [21,22], can liberate these growth factors and promotes angiogenesis.”
BackgroundSelf-citationMoreaux, J., Sprynski, A., Dillon, S. R., Mahtouk, K., Jourdan, M., Ythier, A., Moine, P., Robert, N., Jourdan, E., Rossi, J. F., et al. (2009) · European Journal of Haematology · doi:10.1111/j.1600-0609.2009.01262.x · Cited by 119
Self-citationWuillème, S., Robillard, N., Lodé, L., Magrangeas, F., Beris, H., Harousseau, J., Proffitt, J. H., Minvielle, S., Avet‐Loiseau, H., & du Myélome, F. T. I. F. (2004) · Leukemia · doi:10.1038/sj.leu.2403586 · Cited by 117
Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie, A., Takami, M., Kubo, H., Sekino-Suzuki, N., Kasahara, K., & Sanai, Y. (2007) · Bone · doi:10.1016/j.bone.2007.04.190 · Cited by 116 · cited 1×
“osteoprotegerin (OPG), a decoy receptor for receptor activator of NFkB ligand thus preventing the OPG-mediated inhibition of osteoclastic bone resorption [52].”
BackgroundInhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma
Hose, D., Reme, T. X., Meißner, T., Moreaux, J., Seckinger, A., Lewis, J., Beneš, V., Benner, A., Hundemer, M., Hielscher, T., et al. (2009) · Blood · doi:10.1182/blood-2008-09-178350 · Cited by 110 · cited 1×
“Normal bone marrow plasma cells and myeloma cells were purified as previously published [9,31].”
MethodSelf-citationMahtouk, K., Hose, D., Reme, T. X., Vos, J. D., Jourdan, M., Moreaux, J., Fiol, G., Raab, M. S., Jourdan, É., Grau, V., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208536 · Cited by 109
Self-citationMahtouk, K., Cremer, F. W., Rème, T., Jourdan, M., Baudard, M., Moreaux, J., Requirand, G., Fiol, G., De Vos, J., Moos, M., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209699 · Cited by 105
Self-citationCremer, F. W., Bila, J., Buck, I., Kartal‐Kaess, M., Hose, D., Ittrich, C., Benner, A., Raab, M. S., Theil, A., Moos, M., et al. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20231 · Cited by 98
Self-citationSULFs in human neoplasia: implication as progression and prognosis factors
Bret, C., Moreaux, J., Schved, J., Hose, D., & Klein, B. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-72 · Cited by 90 · cited 1×
“We recently described the ‘‘heparan sulfate code’’ impacting on ligand binding capacity of heparan sulfate proteoglycans and the relevance of sulfatation of the heparan sulfate chains, in particular by the sulfatases SULF1 and SULF2 which selectively remove 6-O-sulfate from heparan sulfate chains thereby altering bind…”
BackgroundSelf-citationSeckinger, A., Meißner, T., Moreaux, J., Goldschmidt, H., Fuhler, G. M., Benner, A., Hundemer, M., Reme, T. X., Shaughnessy, J. D., Barlogie, B., et al. (2009) · Oncogene · doi:10.1038/onc.2009.257 · Cited by 84 · cited 3×
“vascular endothelial growth factor-A (VEGF-A), both produced by normal and malignant plasma cells [8,9].”
BackgroundMethodSelf-citationBret, C., Hose, D., Reme, T. X., Sprynski, A. C., Mahtouk, K., Schved, J., Quittet, P., Rossi, J., Goldschmidt, H., & Klein, B. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07633.x · Cited by 83 · cited 3×
“We recently described the ‘‘heparan sulfate code’’ impacting on ligand binding capacity of heparan sulfate proteoglycans and the relevance of sulfatation of the heparan sulfate chains, in particular by the sulfatases SULF1 and SULF2 which selectively remove 6-O-sulfate from heparan sulfate chains thereby altering bind…”
BackgroundSelf-citationTargeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma
Reijmers, R. M., Groen, R. W. J., Rozemuller, H., Kuil, A., de Haan-Kramer, A., Csikós, T., Martens, A. C. M., Spaargaren, M., & Pals, S. T. (2010) · Blood · doi:10.1182/blood-2009-02-204396 · Cited by 79 · cited 2×
“The relevance of regulated enzymatic activity for proteoheparansulfate synthesis has been demonstrated by knockdown of EXT1 also involved in the chain elongation of heparan sulfate chains [23,53] leading to reduced growth and increased apoptosis in myeloma cells.”
BackgroundTP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3
Shaughnessy, J. D., Zhou, Y., Haessler, J., van Rhee, F., Anaissie, E. J., Nair, B. P., Waheed, S., Alsayed, Y. M., Epstein, J., Crowley, J. J., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07864.x · Cited by 71
Mahtouk, K., Moreaux, J., Hose, D., Reme, T. X., Meißner, T., Jourdan, M., Rossi, J. F., Pals, S. T., Goldschmidt, H., & Klein, B. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-198 · Cited by 70
Self-citationThe 'miss rate' for the analysis of gene expression data
Taylor, J., Tibshirani, R., & Efron, B. (2005) · Biostatistics · doi:10.1093/biostatistics/kxh021 · Cited by 66
A gp130 Interleukin-6 Transducer-Dependent SCID Model of Human Multiple Myeloma
Rebouissou, C., Wijdenes, J., Autissier, P., Tarte, K., Costes, V., Liautard, J., Rossi, J.-F., Brochier, J., & Klein, B. (1998) · Blood · doi:10.1182/blood.v91.12.4727 · Cited by 63
Self-citationGu, Z.-J., Vos, J. D., Rebouissou, C., Jourdan, M., Zhang, X., Rossi, J.-F., Wijdenes, J., & Klein, B. (2000) · Leukemia · doi:10.1038/sj.leu.2401632 · Cited by 61
Self-citationReijmers, R. M., Spaargaren, M., & Pals, S. T. (2013) · The FEBS Journal · doi:10.1111/febs.12180 · Cited by 55 · cited 1×
“The relevance of regulated enzymatic activity for proteoheparansulfate synthesis has been demonstrated by knockdown of EXT1 also involved in the chain elongation of heparan sulfate chains [23,53] leading to reduced growth and increased apoptosis in myeloma cells.”
BackgroundDecay-accelerating factor (CD55): A versatile acting molecule in human malignancies
Mikesch, J., Buerger, H., Simon, R., & Brandt, B. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.04.001 · Cited by 49 · cited 5×
“In order to remove the GPIanchored CD55 and CD59 proteins from the cell surface KMS12-BM and OPM-2 cells (16106 cells suspended in 400 ml PBS) were incubated with 40 mL phospholipase C (100 enzymatic units/ mL; Life Technologies, Darmstadt, Germany) for 1 h at 37uC prior to antibody staining.”
BackgroundInfluentialKirschfink, M., Blase, L., Engelmann, S., & Schwartz‐Albiez, R. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.3.1324 · Cited by 48 · cited 1×
“As serglycins support immune escape mechanisms by inhibition of complement mediated lysis and inhibit bone mineralization they could have role in multiple myeloma pathophysiology as well [54,55].”
BackgroundSelf-citationMeißner, T., Seckinger, A., Reme, T. X., Hielscher, T., Möhler, T., Neben, K., Goldschmidt, H., Klein, B., & Hose, D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1628 · Cited by 45 · cited 1×
“Gene expression analysis Gene expression profiling was performed as published [8,9,26,35].”
MethodSelf-citationAndrulis, M., Dietrich, S., Longerich, T., Koschny, R., Burian, M., Schmitt-Graf, A., Schirmacher, P., Ho, A. D., Dreger, P., & Luft, T. (2012) · Haematologica · doi:10.3324/haematol.2011.061051 · Cited by 42
Self-citationErdmann, M., Wipfler, D., Merling, A., Cao, Y., Claus, C., Kniep, B., Sadick, H., Bergler, W. F., Vlasak, R., & Schwartz‐Albiez, R. (2006) · Glycoconjugate Journal · doi:10.1007/s10719-006-9000-5 · Cited by 39 · cited 2×
“Proteins separated by SDS-PAGE were transferred to PVDF membranes (Millipore, Fl, USA) and subjected to Western blotting [39].”
MethodSelf-citationPANP - a New Method of Gene Detection on Oligonucleotide Expression Arrays
Warren, P., Taylor, D., Martini, P. G. V., Jackson, J., & Bienkowska, J. (2007) · 2007 IEEE 7th International Symposium on BioInformatics and BioEngineering · doi:10.1109/bibe.2007.4375552 · Cited by 35 · cited 1×
“Using the ‘‘presence absence calls with Negative Probesets’’ (PANP) algorithm, we identified 247 genes represented on 426 probe sets expressed at least in one sample [38].”
MethodMalignant plasma cell lines express a functional CD28 molecule
Zhang, X., Olive, D., Vos, J. D., Rebouissou, C., Ghiotto, M., Ferlin, M., & Klein, B. (1998) · Leukemia · doi:10.1038/sj.leu.2400971 · Cited by 31
Self-citationWillhauck‐Fleckenstein, M., Moehler, T. M., Merling, A., Pusunc, S., Goldschmidt, H., & Schwartz‐Albiez, R. (2010) · Angiogenesis · doi:10.1007/s10456-010-9162-4 · Cited by 30 · cited 1×
“org) which contains 1259 genes and further adapted as described previously [37].”
MethodSelf-citationModulated glycosylation of proteoglycans during differentiation of human B lymphocytes
Engelmann, S., Ebeling, O., & Schwartz‐Albiez, R. (1995) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(95)00057-y · Cited by 19 · cited 1×
“As serglycins support immune escape mechanisms by inhibition of complement mediated lysis and inhibit bone mineralization they could have role in multiple myeloma pathophysiology as well [54,55].”
BackgroundSelf-citationDifferential release of proteoglycans during human B lymphocyte maturation
Engelmann, S., & Schwartz‐Albiez, R. (1997) · Carbohydrate Research · doi:10.1016/s0008-6215(97)00115-8 · Cited by 4 · cited 1×
“Also, some GAG chains of myeloma cells consisted of hybrid heparan/chondroitinsulfates [56].”
BackgroundSelf-citation
Cited by
The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma
Glavey, S. V., Manier, S., Natoni, A., Sacco, A., Moschetta, M., Reagan, M. R., Murillo, L. S., Sahin, I., Wu, P., Mishima, Y., et al. (2014) · Blood · doi:10.1182/blood-2014-03-560862 · Cited by 134
“PSGL-1 is the predominant physiologic ligand for P-selectin and L-selectin, but when modified by HECA-452 reactive glycans (CLA), it can also serve as an E-selectin ligand.(24) Posttranslational modifications of PSGL-1 are important for optimal selectin binding; to bind to P-selectin, PSGL-1 requires ana-2,3-sialylate…”
BackgroundThe cancer glycome: Carbohydrates as mediators of metastasis
Glavey, S. V., Huynh, D., Reagan, M. R., Manier, S., Moschetta, M., Kawano, Y., Roccaro, A. M., Ghobrial, I. M., Joshi, L., & O'Dwyer, M. E. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.01.003 · Cited by 116
“has been defined and this has been associated to distinct cytogenetic abnormalities in this disease [158].”
BackgroundTibullo, D., Giallongo, C., Romano, A., Vicario, N., Barbato, A., Puglisi, F., Parenti, R., Amorini, A. M., Saab, M. W., Tavazzi, B., et al. (2020) · Biomolecules · doi:10.3390/biom10050696 · Cited by 69
“An increase in HBP-mediated protein O-glycosylation has also been found in the case of MM [52], although data in this type of cancer are not particularly abundant.”
BackgroundPolyclonal Immunoglobulin G N-Glycosylation in the Pathogenesis of Plasma Cell Disorders
Mittermayr, S., Le, G. N., Clarke, C., Millán‐Martín, S., Larkin, A., O’Gorman, P., & Bones, J. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00768 · Cited by 40
Computational Biology and Chemistry
Behzadi, P., & Bernabò, N. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.83539 · Cited by 40
Metadata
- Authors
- Moehler, T. M., Seckinger, A., Hose, D., Andrulis, M., Moreaux, J., Hielscher, T., Willhauck-Fleckenstein, M., Merling, A., Bertsch, U., Jauch, A., Goldschmidt, H., Klein, B., & Schwartz-Albiez, R.
- Affiliations
- German Cancer Research Center (DE)
- University Hospital Heidelberg (DE)
- Heidelberg University (DE)
- Inserm (FR)
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-12-26
- Volume
- 8
- Issue
- 12
- Pages
- e83719
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3873332
- OpenAlex
- W2067873319
- Cited by
- 17
- References
- 56
- Citations by year
- 2024: 3 · 2022: 2 · 2020: 2 · 2019: 2 · 2017: 1 · 2016: 2 · 2015: 3 · 2014: 2
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Leuka
- Deutsche Forschungsgemeinschaft (SFB/TR79)
- Institut National de la Santé et de la Recherche Médicale
- Bundesministerium für Bildung und Forschung
- José Carreras Leukämie-Stiftung
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- glycome, multiple myeloma, malignant plasma cells, glycosylation, hyperdiploidy, 1q21 gain, 13q14 deletion, chromosomal abnormalities, prognostic factors, survival prediction, autologous stem cell transplantation, high-dose melphalan, therapeutic target
- MeSH terms
- Gene Expression Regulation, Heparan Sulfate, Humans, Mannosyltransferases, Multiple Myeloma, Plasma Cells, Polysaccharides, Cluster Analysis, Glycosylphosphatidylinositols, Gene Dosage, Gene Expression Profiling, Metabolic Networks and Pathways, Glycomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.